Internal Medicine, Gastroenterology · Dallas, TX
NPI
1770528697
Since 2006
Specialty
Internal Medicine, Gastroenterology
Code 207RG0100X
Group practices
2
Medicare group memberships
Hospitals
5
Hospital affiliations
1411 N Beckley Ave, Pavilion III Ste 268
Dallas, TX, 75203
Phone (214) 947-4400
Groups this clinician bills Medicare through
Medicare paid, 2024
$60K
705 services
Medicare patients, 2024
326
Average age 70
Drug cost, 2024
$2.7M
2,310 prescriptions
Company payments, 2025
$302K
From 22 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Parvez Mantry was code 99214 (office e&m - established), 328 times for 217 patients. In total Parvez Mantry billed 705 services in 34 codes, and Medicare paid $60K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2021-10-19.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99214 Office E&M - Established | Office | 328 | 217 | $80.72 | $26K |
| 99232 Hospital E&M - Subsequent | Facility | 80 | 31 | $58.13 | $4,650 |
| 99204 Office E&M - New | Office | 65 | 65 | $114.86 | $7,466 |
| 91200 Standard X-ray | Office | 44 | 44 | $21.79 | $959 |
| 99213 Office E&M - Established | Office | 32 | 30 | $56.20 | $1,798 |
| 99233 Hospital E&M - Subsequent | Facility | 17 | 11 | $92.05 | $1,565 |
| 99222 Hospital E&M - Initial | Facility | 15 | 15 | $95.65 | $1,435 |
| 43244 Upper GI Endoscopy | Facility | 14 | 12 | $181.50 | $2,541 |
| 43239 Upper GI Endoscopy | Facility | 14 | 14 | $76.29 | $1,068 |
By year: 2022 $89K for 1,006 services; 2023 $62K for 679 services; 2024 $60K for 705 services.
Medicare prescription drug claims, 2024
In 2024, the drug Parvez Mantry prescribed most often to Medicare patients was Tacrolimus, with 274 prescriptions and refills. In total Parvez Mantry wrote 2,310 Medicare prescriptions that cost $2.7M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Tacrolimus Generic | 274 | 450 | 49 | $26K |
| Ursodiol Generic | 269 | 407 | 50 | $40K |
| Spironolactone Generic | 167 | 335 | 56 | $1,830 |
| Xifaxan Rifaximin | 130 | 132 | 21 | $394K |
| Furosemide Generic | 123 | 213 | 46 | $430 |
| Mycophenolate Mofetil Generic | 122 | 158 | 19 | $6,424 |
| Pantoprazole Sodium Generic | 98 | 193 | 26 | $395 |
| Vemlidy Tenofovir Alafenamide | 81 | 87 | Under 11 | $119K |
| Rezdiffra Resmetirom | 64 | 68 | 17 | $277K |
| Ozempic Semaglutide | 54 | 63 | 11 | $52K |
| Rosuvastatin Calcium Generic | 54 | 81 | Under 11 | $160 |
| Vitamin D2 Ergocalciferol (Vitamin D2) | 50 | 63 | 12 | $332 |
| Entecavir Generic | 50 | 72 | Under 11 | $3,510 |
| Lactulose Generic | 47 | 59 | 14 | $1,833 |
| Epclusa Sofosbuvir/Velpatasvir | 41 | 41 | 12 | $960K |
Brand drugs: - claims; generic drugs: 1,752 claims; opioid claims: 11.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Parvez Mantry $302K ($302K in general payments such as food, travel and fees) from 22 companies. The largest payer was Madrigal Pharmaceuticals with $104K.
| Company | Payments | Amount |
|---|---|---|
| Madrigal Pharmaceuticals MDGL | 55 | $104K |
| Novo Nordisk Inc NVO | 29 | $74K |
| Amgen Inc. AMGN | 59 | $40K |
| Gilead Sciences, Inc. GILD | 41 | $28K |
| Intercept Pharmaceuticals, Inc. | 20 | $20K |
| Ipsen Biopharmaceuticals, Inc IPN.PA | 12 | $19K |
| Boston Scientific Corporation BSX | 7 | $8,892 |
| Abbvie Inc. ABBV | 18 | $6,223 |
| Eisai Inc. 4523.T | 5 | $2,003 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC BHC | 4 | $206 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.